In‑Vitro Contractile Force Sensing Platform for Quantitative Tissue Mechanics (In‑Vitro Contractile Force Indicator, Tech ID: 21‑024)
Technology Overview: This technology provides an in‑vitro contractile force indicator that enables quantitative measurement of cellular and tissue‑level mechanical forces. The platform converts contractile activity into measurable signals, allowing researchers to monitor functional performance of engineered tissues or cell cultures in real time. The system is particularly useful for evaluating muscle, cardiac, and cytoskeletal behavior under physiological or pharmacological conditions.
Industry Pain Point: Existing in‑vitro assays inadequately capture mechanical functionality, limiting translational relevance of tissue models.
NJIT Solution: This technology enables direct, quantitative force measurement, improving assessment of tissue function and drug response.
Key Features & Advantages
- Quantitative measurement of contractile forces
- Real‑time functional readout
- Compatible with in‑vitro tissue models
- Enables mechanobiology‑focused drug testing
Development Stage: TRL 4–5 – Laboratory validation completed.
Target Markets
- Drug discovery and screening
- Tissue engineering research
- Mechanobiology platforms
Market Opportunity
- Global cell‑based assay market (2026): ~$24B
- CAGR: ~9–10%
- Projected market size (2035): ~$50–55B
Commercial & IP Details
Inventors: Katherine Coombs, Jonathan Grasman, Cassandra Martin, Jessica Pridmore